How Much Does Ozempic Cost? (2026)

Ozempic List Price Breakdown

Ozempic is manufactured by Novo Nordisk and FDA-approved for type 2 diabetes management. It is widely prescribed off-label for weight loss. The wholesale acquisition cost (WAC) — what pharmacies pay before discounts — is $998/month regardless of dose.

All four Ozempic pen doses carry the same list price:

• 0.25 mg (starting dose, weeks 1-4): $998/month
• 0.5 mg (maintenance dose): $998/month
• 1 mg (escalated dose): $998/month
• 2 mg (maximum dose): $998/month

For context, the same medication costs approximately $59/month in Germany, $155/month in Canada, and $89/month in the UK. The U.S. list price is roughly 10x what patients pay in other developed countries.

Novo Nordisk has not announced any list price reductions for 2026, though increasing competitive pressure from Eli Lilly's Zepbound and the introduction of Medicare coverage may force changes in the coming years.

Ozempic Cost With Insurance

Your out-of-pocket cost with insurance depends on your plan type, formulary tier, and whether you have a deductible to meet. Here are typical ranges:

Important: Ozempic is FDA-approved only for type 2 diabetes. If your doctor prescribes it off-label for weight loss, your insurance may deny coverage. In that case, ask your doctor about Wegovy (same drug, weight loss indication) or Zepbound, which insurers are more likely to cover for obesity.

Self-Pay and Savings Programs

If you don't have insurance or your plan doesn't cover Ozempic, several options can significantly reduce your cost:

Compounded Semaglutide Alternatives

Compounded semaglutide has been available from compounding pharmacies and telehealth providers at significantly lower prices — typically $149-$499/month. However, the landscape has changed dramatically in 2025-2026:

• The FDA declared the semaglutide shortage officially over in early 2025, removing the legal basis for 503A compounding under the shortage exemption.
• The FDA has issued warning letters to 50+ compounding pharmacies and filed enforcement actions against several large compounders.
• Some 503B outsourcing facilities continue to compound semaglutide under different legal arguments, but their long-term legality remains uncertain.

Our position: While compounded semaglutide offered significant savings, the regulatory risk means patients should plan for transitioning to FDA-approved alternatives. Oral Wegovy at $149/month and Zepbound via LillyDirect at $349/month now offer competitive pricing without the legal uncertainty. Read our full compounded vs brand comparison.

Medicare Coverage Starting July 2026

In a landmark policy change, Medicare will begin covering GLP-1 medications for weight loss starting July 1, 2026. This affects approximately 7.4 million Medicare beneficiaries with obesity (BMI 30+) or overweight (BMI 27+) with related health conditions.

Under the bridge program:

• Covered medications include Wegovy (semaglutide) and Zepbound (tirzepatide)
• Ozempic itself is covered for diabetes patients, not directly for weight loss under this program
• Estimated copay: $35-$50/month under most Part D plans
• Prior authorization will likely be required, including BMI documentation and failed lifestyle intervention

If you are 65+ and currently paying out-of-pocket for Ozempic, the Medicare bridge program could reduce your cost by over 90%. Talk to your Part D plan about formulary updates expected in Q2 2026. Read our full Medicare GLP-1 coverage guide.

How Ozempic Compares to Alternatives

Ozempic is not your only option for GLP-1 treatment. Here is how it stacks up against other medications in terms of cost and effectiveness:

• Wegovy ($1,349/month list): Same drug as Ozempic but FDA-approved for weight loss. Higher dose (2.4mg vs 2mg max). Better insurance coverage for obesity treatment. See Wegovy pricing.
• Zepbound ($1,059/month list, $349 self-pay): Tirzepatide targets both GLP-1 and GIP receptors. Clinical trials show 22.5% average weight loss vs 15% for semaglutide. LillyDirect makes it cheaper than Ozempic for self-pay patients. See Zepbound pricing.
• Mounjaro ($1,023/month list): Same drug as Zepbound but approved for diabetes. If you have type 2 diabetes, Mounjaro may have better insurance coverage than Ozempic. See Mounjaro pricing.
• Rybelsus ($936/month list): Oral semaglutide tablet for diabetes. Lower efficacy than injectable Ozempic at currently approved doses. Does not require injections. See Rybelsus pricing.